Literature DB >> 1451718

Phenytoin metabolism during pregnancy.

M J Eadie1, G E McKinnon, R G Dickinson, W D Hooper, C M Lander.   

Abstract

The steady-state 72 h urinary excretion of various phenytoin metabolites has been measured in 10 epileptic women, whose plasma phenytoin concentrations relative to the phenytoin dose fell during pregnancy and rose again post-partum. In later pregnancy and post partum, a mean of 61.3% and 48.9%, respectively, of the total daily phenytoin dose was eliminated as 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Even though p-HPPH accounts for not much more than half the total daily phenytoin dose, increased excretion of this metabolite sufficed to account for the elimination of the entire increase in the dose of phenytoin required during pregnancy. There was no definite increase in the excretion of any other (minor) metabolite measured. Thus pregnancy seems not to enhance uniformly the capacity of the various metabolic pathways of phenytoin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1451718     DOI: 10.1007/bf02220614

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Pregnancy-induced changes in drug metabolism in epileptic women.

Authors:  M Bologa; B Tang; J Klein; A Tesoro; G Koren
Journal:  J Pharmacol Exp Ther       Date:  1991-05       Impact factor: 4.030

2.  Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding.

Authors:  M S Yerby; P N Friel; K McCormick; M Koerner; M Van Allen; A M Leavitt; C J Sells; J A Yerby
Journal:  Epilepsy Res       Date:  1990-04       Impact factor: 3.045

3.  Plasma drug level monitoring in pregnancy.

Authors:  M J Eadie; C M Lander; J H Tyrer
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

4.  Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism.

Authors:  J H Maguire
Journal:  Epilepsia       Date:  1988 Nov-Dec       Impact factor: 5.864

5.  Hydantoin ring glucuronidation: characterization of a new metabolite of 5,5-diphenylhydantoin in man and the rat.

Authors:  R G Smith; G D Daves; R K Lynn; N Gerber
Journal:  Biomed Mass Spectrom       Date:  1977-08

6.  Plasma antiepileptic drug concentrations during pregnancy.

Authors:  C M Lander; M J Eadie
Journal:  Epilepsia       Date:  1991 Mar-Apr       Impact factor: 5.864

7.  Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin.

Authors:  R G Dickinson; W D Hooper; M Patterson; M J Eadie; B Maguire
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

8.  Phenytoin metabolism in pregnancy.

Authors:  N K Kochenour; M G Emery; R J Sawchuk
Journal:  Obstet Gynecol       Date:  1980-11       Impact factor: 7.661

9.  Plasma anticonvulsant concentrations during pregnancy.

Authors:  C M Lander; V E Edwards; M J Eadie; J H Tyrer
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

10.  Determination of 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (Dihydrodiol) and quantitative studies of phenytoin metabolism in man.

Authors:  J H Maguire; B L Kraus; T C Butler; K H Dudley
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.